Navigation Links
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
Date:12/10/2008

The above mentioned studies and data represent the latest results of clinical research for each treatment and are not necessarily part of the indicated licence in each country. For detailed label information, visit the website of your health authority or the EMEA website http://www.emea.europa.eu/

Note to Editors

Breast cancer is the most common cancer among women worldwide.(i) Each year more than one million new cases of breast cancer are diagnosed worldwide, and nearly 400,000 people will die of the disease annually. (ii) In HER2- positive breast cancer, increased quantities of the HER2 protein are present on the surface of the tumour cells. This is known as 'HER2-positivity'. High levels of HER2 are present in a particularly aggressive form of the disease which responds poorly to chemotherapy. Research shows that HER2-positivity affects approximately 20-30 percent of women with breast cancer.(iii)

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the

central nervous system. In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
5. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
6. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
7. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
11. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that it expects revenues for the ... bringing expected full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... , Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), ... that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... The terms of the acquisition were not disclosed. ... company providing a wide range of sleep, mobility, and respiratory ...
(Date:1/14/2014)... 14, 2014 NineSigma , Inc., the leading ... Innovation Leadership Summit , May 14-16, 2014 at the ... Ohio . This is the ... to breakthrough achievements through open innovation. Participants will learn ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... April 27 AstraZeneca LP and AstraZeneca ... resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug ... by the Food and Drug Administration (FDA), the Departments ... Fraud Enforcement Action Team (HEAT) announced today.  Such unapproved ...
... April 27 /PRNewswire-Asia-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" ... traditional Chinese medicines ("TCM"), today announced,the appointment of Mr. Dianjun ... , and that the Company has established nominating and compensation,committees. , ... ...
Cached Medicine Technology:Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 2Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 3Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 4Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 5Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 6Renhuang Appoints New Director and Establishes Nominating and Compensation Committee 2Renhuang Appoints New Director and Establishes Nominating and Compensation Committee 3
(Date:4/24/2014)... Richard Plemper, a professor in the new Institute ... received a five-year, $2.83 million federal grant to ... infection. , The grant from the Eunice Kennedy ... Development of the National Institutes of Health will ... anti-RSV drug and at least one distinct alternative ...
(Date:4/24/2014)... Ill. It is better to give than to receive ... giving, a new study suggests. , The study found that ... as giving their money to family members, are less likely ... from taking risks or keeping the money for themselves. , ... the National Academy of Sciences . , The study focused ...
(Date:4/24/2014)... 2009 the influenza pH1N1 virus caused the first flu ... in May 2009 and killed more than 50 people ... Finns mainly during flu epidemics (winter/spring seasons). , ... serious complicated illnesses. World Health Organization has recommended Tamiflu ... The disadvantage of this drug is that it targets ...
(Date:4/23/2014)... for a new experimental drug to treat acute ... with CPX-351, a combination of the chemotherapeutic drugs ... patients treated with the standard drug formulation. ... aggressive blood cancer with very low rates of ... Lancet, M.D., senior member of the Department of ...
(Date:4/23/2014)... exposed to high-energy particles, simulating conditions astronauts would face ... attention and slower reaction times, even when the radiation ... cognitive impairments which affected a large subset, but ... be linked to protein changes in the brain, the ... in humans, suggest it may be possible to develop ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... don,t delay surgery, research shows , FRIDAY, June 4 ... a suddenly inflamed gallbladder improves survival and reduces costs ... Dr. Taylor S. Riall, associate professor of surgery at ... colleagues analyzed data on 29,818 Medicare beneficiaries hospitalized for ...
... and heart rate, but decreases stress hormone levels, researchers find ... gets angry it is often possible to see them physically ... is going on inside the body. , The new study ... when they are angry, right down to the cellular level. ...
... ... Resources, Inc. (GDAR) CFO Graham Larmer. , ... Hollywood, FL (PRWEB) June 4, 2010 -- Golden Age Resources, Inc., (pink sheets; ... Geometrix Engineering, Inc. of Hollywood, FL to finalize the development of Cobra. This is a ...
... ... desktop virtualisation software SoftXpand, as the exclusive distributor for supplying its award-winning multi-user solution ... ... has been appointed by Miniframe, supplier of innovative desktop virtualisation software SoftXpand, as the ...
... Patent ... ... Inc. (Chrono), a privately held company that pioneers chrono therapeutic health care products, announced ... systems and applications. , , ,Guy DiPierro, CEO of Chrono, noted that this new ...
... ... the tablets and capsules they often struggle to take. Publix is launching Pill Glide in all ... both strawberry and grape flavors. , ... MD (PRWEB) June 4, 2010 -- FLAVORx Inc . announced today the launch of its ...
Cached Medicine News:Health News:Removing Gallbladder Sooner Cuts Costs, Readmissions 2Health News:Anger Spurs Surprising Changes in the Body 2Health News:Gulf Oil Spill Goes from Disaster to Catastrophe 2Health News:London Web Expands Green IT with SoftXpand Desktop Virtualisation Solution 2Health News:London Web Expands Green IT with SoftXpand Desktop Virtualisation Solution 3Health News:US Patent Granted To Chrono Therapeutics Inc. For Its Chrono-Pharmacological Drug Delivery Systems And Applications 2Health News:Publix Pharmacy Now Offers Pill Glide, an Innovative New Way for Children and Adults to Take Vitamins, Supplements and Medications 2Health News:Publix Pharmacy Now Offers Pill Glide, an Innovative New Way for Children and Adults to Take Vitamins, Supplements and Medications 3
... Radianse single-use active-RFID tag combines ... of medical consumables with the ... reusable active-RFID tags. It can ... wrist band, fit comfortably on ...
... recreational venues and more can use ... data capture that boosts efficiency and ... errors. RFID wristbands can also prevent ... venues as well as be used ...
... Infant Protection System helps protect infants, patients, ... the operating efficiencies, cost savings, and overall ... busy and constrained healthcare facilities., And with ... reliable and versatile solution, but also unique-skin ...
... With the ProtecPoint Exit Alerting System, ... staff) and assets (e.g. medical equipment), ... your facility. With this form of ... cost savings, operating efficiencies, and overall ...
Medicine Products: